Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy

被引:12
作者
Mozarowski, Paul [1 ]
Rasaiah, Bhubendra [1 ]
Reed, Melissa [2 ,3 ]
Lewis, Alexis [2 ,4 ]
Walde, Natalie [2 ]
Voutsadakis, Ioannis A. [5 ,6 ]
机构
[1] Sault Area Hosp, Dept Pathol, Sault Ste Marie, ON P6B 0A8, Canada
[2] Sault Area Hosp, Clin Trials Unit, Sault Ste Marie, ON P6B 0A8, Canada
[3] Univ Ottawa, Sch Med, Fac Med, Ottawa, ON KK1H 8M5, Canada
[4] Algoma Univ, Dept Biol, Sault Ste Marie, ON P6A 2G4, Canada
[5] Sault Area Hosp, Algoma Dist Canc Program, Sault Ste Marie, ON P6B 0A8, Canada
[6] Northern Ontario Sch Med, Div Clin Sci, Sect Internal Med, Sudbury, ON P3E 2C6, Canada
关键词
tumor budding; neo-adjuvant treatment; breast cancer; prognosis; marker; EPITHELIAL-MESENCHYMAL TRANSITION; MICROENVIRONMENT; CELLS;
D O I
10.3390/jcm10040827
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Isolated tumor cells or small clusters of tumor cells observed in the vicinity of the main tumor mass in pathology sections, termed tumor budding, are common in cancers and have been associated with prognosis in some settings. This study examined the clinical associations and treatment efficacy implications of tumor budding in breast cancer patients receiving neo-adjuvant therapy. Methods: Breast cancer patients that received neo-adjuvant therapy before definitive surgical treatment in a single cancer center over a 7-year period were included, and their records were reviewed. Data extracted included patient demographics, tumor characteristics and pathologic response to treatment at surgery. The initial breast cancer biopsy before any therapy was reviewed by two pathologists, and a hot spot area was evaluated for tumor budding (defined as 1 to 5 cancer cells observed detached from the main tumor mass). Results: Seventy-five patients who received neo-adjuvant therapy (73 received chemotherapy and 2 received hormonal therapy) were included. Tumor budding was observed in two-thirds of the patients. There were no significant differences in patient (age and menopause status) and tumor (stage, histology and molecular sub-type equivalent) characteristics between the group that had tumor budding and the group that did not have tumor budding in the pre-treatment biopsy. Likewise, no statistically significant differences were observed in the frequency of complete or partial responses between the two groups. Conclusion: In this cohort of breast cancer patients receiving neo-adjuvant therapy, tumor budding was frequent, but it was not associated with tumor characteristics or pathologic responses to treatment. The value of tumor budding as a prognostic factor in the neo-adjuvant setting within the general breast cancer population could not be confirmed, but such a value in specific sub-groups deserves further investigation, given the pathophysiologic rationale and data from other settings.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 30 条
[1]   Tumor budding in infiltrating breast carcinoma: Correlation with known clinicopathological parameters and hormone receptor status [J].
Agarwal, Radhika ;
Khurana, Nita ;
Singh, Tejinder ;
Agarwal, P. N. .
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2019, 62 (02) :222-225
[2]   Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience [J].
Battisti, Nicolo Matteo Luca ;
Tong, Daniel ;
Ring, Alistair ;
Smith, Ian .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (02) :401-408
[3]   57% decline in Rhode Island invasive breast cancer mortality between 1987 and 2017: mammography predominates in preventing mortality [J].
Cady, Blake ;
Fulton, John P. .
BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (01) :135-147
[4]   The prognostic influence of tumour budding in Western patients with stage II colorectal cancer [J].
Cangucu, Augusto Leite ;
Valerio, Ediel ;
Peixoto, Roberto Bonfim Pimenta ;
Felismino, Tiago Cordeiro ;
de Mello, Celso Abdon Lopes ;
Neotti, Tatiane ;
Calsavara, Vinicius Fernando ;
de Macedo, Mariana Petaccia ;
Aguiar Junior, Samuel ;
Riechelmann, Rachel .
ECANCERMEDICALSCIENCE, 2020, 14
[5]   Molecular and pathogenetic aspects of tumor budding in colorectal cancer [J].
Dawson, Heather ;
Lugli, Alessandro .
FRONTIERS IN MEDICINE, 2015, 2 :11
[6]   Cancer statistics for African Americans, 2019 [J].
DeSantis, Carol E. ;
Miller, Kimberly D. ;
Sauer, Ann Goding ;
Jemal, Ahmedin ;
Siegel, Rebecca L. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (03) :211-233
[7]   Tumor Budding: The Name is EMT. Partial EMT. [J].
Grigore, Alexandru Dan ;
Jolly, Mohit Kumar ;
Jia, Dongya ;
Farach-Carson, Mary C. ;
Levine, Herbert .
JOURNAL OF CLINICAL MEDICINE, 2016, 5 (05) :51-+
[8]   The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer [J].
Gujam, F. J. A. ;
McMillan, D. C. ;
Mohammed, Z. M. A. ;
Edwards, J. ;
Going, J. J. .
BRITISH JOURNAL OF CANCER, 2015, 113 (07) :1066-1074
[9]   Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy [J].
Houssami, Nehmat ;
Macaskill, Petra ;
von Minckwitz, Gunter ;
Marinovich, Michael L. ;
Mamounas, Eleftherios .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (18) :3342-3354
[10]   Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma [J].
Kadota, Kyuichi ;
Yeh, Yi-Chen ;
Villena-Vargas, Jonathan ;
Cherkassky, Leonid ;
Drill, Esther N. ;
Sima, Camelia S. ;
Jones, David R. ;
Travis, William D. ;
Adusumilli, Prasad S. .
CHEST, 2015, 148 (03) :711-721